M. Reddy

发表

(Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies.

E. Reddy, M. Reddy, Balaiah Akula, 2012, Journal of medicinal chemistry.

Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity.

K. Gumireddy, E. Reddy, M. Reddy, 2004, Bioorganic & medicinal chemistry letters.

A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.

E. Reddy, S. Baker, E. Sloand, 2010, Genes & cancer.

Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)

E. Reddy, S. Baker, M. Reddy, 2014, Journal of medicinal chemistry.

Ruthenium carbonyl containing 4-pyrones as potent anticancer agents

M. Reddy, S. Cosenza, D. Szalda, 2018, Journal of Organometallic Chemistry.

Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.

E. Reddy, J. Gallo, M. Reddy, 2013, Journal of medicinal chemistry.

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells

E. Reddy, J. Groopman, X. Zhang, 2009, Oncogene.

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity.

E. Reddy, M. Reddy, Balaiah Akula, 2011, Journal of medicinal chemistry.

Rigosertib in myelodysplastic syndromes (MDS)

A. Raza, A. Ali, S. Fruchtman, 2016 .

B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell development

Edward Y. Chen, E. Chen, Avi Ma’ayan, 2014, Proceedings of the National Academy of Sciences.

Glycal–ruthenium carbonyl clusters: Syntheses, characterization, and anticancer activity

R. D. Adams, M. Reddy, S. Cosenza, 2009 .

Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP

E. Reddy, M. Sheikh, W. Jin, 2008, Oncogene.

Synthesis and characterization of triruthenium carbonyl incorporating 4-pyridones as potential antitumor agents

M. Reddy, S. Cosenza, D. Szalda, 2018, Journal of Organometallic Chemistry.

Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent.

E. Reddy, M. Reddy, Balaiah Akula, 2013, Organic & biomolecular chemistry.

Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140.

E. Reddy, Y. Lieu, M. Reddy, 2014, European journal of cancer.

Dual Inhibition of CDK4/Rb and PI3K/AKT/mTOR Pathways by ON123300 Induces Synthetic Lethality in Mantle Cell Lymphomas

E. Reddy, S. Baker, S. Parekh, 2015, Leukemia.

A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent.

R. Jain, E. Reddy, A. Aggarwal, 2020, Molecular cell.

Mechanism of action of rigosertib does not involve tubulin binding

R. Jain, E. Reddy, A. Aggarwal, 2019, bioRxiv.

Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents.

E. Reddy, M. Reddy, S. Cosenza, 2008, Journal of medicinal chemistry.

Syntheses, structures, and anticancer activity of novel organometallic ruthenium–maltol complexes

M. Reddy, S. Cosenza, D. Szalda, 2012 .

Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1.

K. Gumireddy, E. Reddy, M. Reddy, 2005, Bioorganic & medicinal chemistry.

Abstract LB-108: Targeting the Ras-Binding domain of RAS effector proteins by a small molecule inhibitor, Rigosertib

D. Morrison, E. Reddy, S. Baker, 2014 .

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

K. Gumireddy, E. Reddy, S. Baker, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors.

E. Reddy, J. Gabriel, R. Boominathan, 2008, Bioorganic & medicinal chemistry.

Solvent Dependent Dehydrating Condensation of Benzylsulfonyl Acetic Acids

E. Reddy, M. Reddy, N. S. Reddy, 2004 .

Design, synthesis, and biological evaluation of (E)- and (Z)-styryl-2-acetoxyphenyl sulfides and sulfones as cyclooxygenase-2 inhibitors.

E. Reddy, R. Boominathan, M. Reddy, 2005, Bioorganic & medicinal chemistry.

Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues

E. Reddy, J. Gallo, Q. Zhou, 2012, Investigational New Drugs.

Radiation Protection by a New Chemical Entity, Ex-Rad™: Efficacy and Mechanisms

E. Reddy, M. Perkins, T. Kao, 2009, Radiation research.

Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.

S. Jagannath, E. Reddy, S. Parekh, 2016, Cancer research.

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

Kiranmai Gumireddy, Jiandong Jiang, K. Gumireddy, 2005, Cancer cell.

Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase.

E. Reddy, M. Truongcao, M V Ramana Reddy, 2010, Bioorganic & medicinal chemistry.

Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).

R. Jain, A. Aggarwal, Shashidhar S Jatiani, 2016, Bioorganic & medicinal chemistry.

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling

K. Dutta, P. Vogt, A. Aggarwal, 2016, Cell.

ON01210.Na (Ex-RAD®) Mitigates Radiation Damage through Activation of the AKT Pathway

E. Reddy, M. Reddy, S. Cosenza, 2013, PloS one.

Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models

J. Chipuk, J. Gallo, Q. Zhou, 2014, Molecular Cancer Therapeutics.

Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Novel Anticancer Agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for Brain Tumor Chemotherapy

James M. Gallo, E. Reddy, J. Gallo, 2012, Pharmaceutical Research.

Integrated Pharmacokinetic-Driven Approach to Screen Candidate Anticancer Drugs for Brain Tumor Chemotherapy

J. Gallo, M. Reddy, J. Sharma, 2012, The AAPS Journal.

Abstract 4519: Targeting of cyclin D/Rb/E2F and PI3K/AKT/MTOR pathways with ON 123300 as a therapeutic strategy for mantle cell lymphoma

E. Reddy, S. Baker, S. Parekh, 2014 .

Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Novel Anticancer Agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for Brain Tumor Chemotherapy

J. Gallo, Q. Zhou, P. Guo, 2012, Pharmaceutical Research.

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling

K. Dutta, P. Vogt, A. Aggarwal, 2016, Cell.

M. Reddy, Balaiah Akula, S. Cosenza, 2012, Journal of medicinal chemistry.